You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

June 30, 2021

Thailand Decriminalizes Kratom in Amended Narcotics Act

Subscribe to Updates

Recently enacted Thai legislation has removed Mitragyna speciosa, commonly known as “kratom,” from the list of controlled narcotics under the Narcotics Act B.E. 2522 (1972), effectively decriminalizing the consumption, production, disposal, import, export, and possession of kratom, for any purpose and in any quantity or form, effective August 24, 2021. The Narcotics Act (No. 8) B.E. 2564 (2021) was published in the Government Gazette on May 26, 2021, and will come into effect 90 days later. This change comes some two years after Thailand allowed the use of cannabis and kratom for medical proposes with the Narcotics Act (No. 7) B.E. 2562 (2019).

Nevertheless, it appears that kratom will still be subject to some level of regulation. On June 1, 2021, the government announced that draft legislation regulating the sale and use of kratom plants was approved by the cabinet. The draft is expected to set licensing requirements for growing, selling, and importing or exporting kratom for industrial use, while also prohibiting the sale of kratom to minors and pregnant or nursing women, and clarifying issues such as labeling, advertising, and selling channels. It is also important to note that the use of kratom for production of food and beverages under the control of the Thai Food and Drug Administration remains prohibited unless the Ministry of Public Health Notification RE: Prohibited List of Plants for Use in Food is amended.

Kratom is a plant indigenous to Southeast Asia which some consider to have potential medicinal applications due to the presence of mitragynine—an alkaloid anecdotally said to boost energy, ease pain, and assist with opiate withdrawal. However, these claims have not been properly studied due to its relative international obscurity and illegality in many of the countries to which it is native. Kratom is an addictive substance and has a risk of dangerous contraindications when consumed with other substances, which has resulted in such prohibition.

In Thailand, restrictions were first implemented under the Kratom Plant Act B.E. 2486 (1943) and kratom was subsequently listed as a Category 5 narcotic in the Narcotics Act B.E. 2522 (1979), effectively prohibiting all consumption, cultivation, trade, and distribution.

The new legislation removes kratom from the Narcotics Act list of prohibited substances on the basis that its consumption is a part of traditional Thai cultural norms, and that it is not categorized as a narcotic in the UN Single Convention on Narcotic Drugs (an absence that is also reflected in the narcotics laws of several other countries, including federal laws in the United States).

The delisting of kratom as a narcotic will, in turn, trigger the rarely-used Section 2 of the Criminal Code, which expunges convictions and ends pending sentences or ongoing punishments stemming from an activity that is subsequently legalized.

The relaxation of restrictions on kratom (and on cannabis) is part of a larger strategic push for legal reform to make the law to reflect current societal conditions and expectations. The Act on Legislative Drafting and Evaluation of Law B.E. 2562 (2019) provides a clear indication of this by calling on government agencies to consider drafts to repeal or amend laws that are no longer necessary, are inconsistent with the current social context, or obstruct livelihoods or occupations, while also ensuring that criminal penalties do not impose too heavy a burden. Moreover, this act authorizes the General Assembly of Supreme Court Justices to exercise its discretion to decide against imposing criminal sanctions or consider lesser punishments than prescribed in the law when it believes that the provision is no longer needed, is inconsistent with the present social context, or hinders livelihoods or occupations. It is likely that this push for modernization will result in further legislative changes across a broad scope of legal measures in the future.

Tilleke & Gibbins will continue to monitor this development, and similar developments in future, and we keep you updated as the situation developments. For any queries about regulatory or contentious matters relating to kratom in Thailand, please contact the firm’s Bangkok office on [email protected].

Related Professionals

Industries

Life Sciences

Practices

Dispute Resolution and Litigation

Regulatory Affairs

Location

RELATED INSIGHTS​ 

October 25, 2023
One significant development in the health sector in Indonesia is the use of information technology and communication in the implementation of health efforts—particularly digital health services such as telehealth and telemedicine integrated into the country’s National Health Information System. This development was addressed in a major new piece of legislation for the healthcare sector in Indonesia. Enacted in August 2023, Law No. 17 of 2023 concerning Health (the “Health Law”) provides the updates needed to support the development of healthcare services in Indonesia. Under the Health Law, health information system (HIS) providers must: Carry out processing of data and health information in the territory of Indonesia, except for certain limited and specific processing activities that may be conducted outside Indonesia when permitted by the relevant authorities and in compliance with relevant regulations. Ensure the reliability of its HIS, including availability, security, maintenance, and integration with Indonesia’s National Health Information System. Provide quality health data and information. Process data and health information, which includes planning, collection, storage, inspection, transfer, utilization, and destruction. Record its data- and information-processing history. Protect every person’s data and health information. Obtain approval from the relevant personal data subject or comply with relevant regulations if the processing of data and health information involves an individual’s health data. Inform the data owner if there is a failure to protect data and individual health information. The Health Law’s personal data protection requirements listed above appear to be aligned with the provisions in Law No. 27 of 2022 concerning Personal Data Protection (the “PDP Law”). Under this law, data and information relating to health are identified as “specific personal data,” the processing of which carries a high potential risk of impacting the relevant personal data subject. In the implementation of digital health services, patients’ personal data or medical records
Read More
October 19, 2023
Cambodia’s Law on Food Safety came into force on June 8, 2022. This law has been widely regarded as a major legal development of the food safety framework in Cambodia, providing new rules, clarifying existing rules, and setting a clear framework for its implementation and enforcement. In addressing some of the key features of this new law shortly after it was passed in 2022, we remarked that we eagerly await implementing regulations. Since then, various regulations have been adopted, such as two regulations (Sub-Decree No. 13 and Prakas No. 80) on food surveillance, recalls, and seizure. These implementing rules are essential in ensuring that enforcement officers can remove noncompliant and unsafe foods from the market. Another key aspect of the Law on Food Safety is that it requires Khmer-language labeling on prepackaged food products. There has been a notable increase in the inclusion of Khmer labeling on food products in the market since June 2022, but noncompliance is still considerable, especially for imported foods. Further interesting labeling rules set by the Law on Food Safety include a requirement to provide nutrition information. This requirement has not yet been widely adopted, with many in the industry highlighting that the details of this labeling requirement are not clear. Indeed, the relevant article of the Law on Food Safety itself only sets the requirement for food products to bear nutrition labeling and does not spell out what detailed information should be provided or in what manner. However, a prakas (ministerial regulation) adopted months prior to the Law on Food Safety does set out clear guidance on nutrition labeling. As long as this earlier regulation is not replaced or abrogated, and as far as it does not conflict with later laws or regulations, it can be relied upon for guidance. What are the
Read More
September 20, 2023
Thailand is preparing to open its first renewal period for drug marketing authorizations (MAs) since the passage of the Drug Act (No. 6) B.E. 2562 (2019). Before 2019, MAs for pharmaceuticals and vaccines in Thailand had lifelong validity. The 2019 Drug Act stipulated that all new MAs would be valid for seven years and could be renewed. The 2019 law also set out expiration dates for existing pharmaceutical products registered and approved prior to the implementation of the law (i.e., before October 13, 2019): Drug MAs issued before January 1, 1997, expire on October 13, 2024. Drug MAs approved between January 1, 1997, and December 31, 2007, expire on October 13, 2026. Drug MAs approved between January 1, 2008, and October 13, 2019, expire on October 13, 2028. Based on these dates, the first renewal period for drug MAs will commence in the fourth quarter of 2023. To facilitate the renewal process, the Thai Food and Drug Administration (FDA) has publicized draft regulations and notifications on the required application form and documents, the rules and conditions, and the process for renewing an MA. In May 2023, the Thai FDA issued Ministerial Regulation Re: Renewal of Drug MA Licenses B.E. 2566 (2023) to prescribe the essential requirements for filing a renewal application: To renew a drug MA, holders must submit their renewal application to the Thai FDA within the one-year period before the MA’s expiration date. Renewal applications can only be submitted online via the Thai FDA’s electronic system. The Thai FDA will grant approval for an MA renewal if the following conditions are satisfied: The documents in relation to efficacy and safety are up-to-date, accurate, and in accordance with academic principles. The specification and analytical method comply with the official pharmacopeias as prescribed in the Drug Act, as amended.
Read More
September 15, 2023
In May 2023, Thailand issued a regulation on conditional approval for emergency use of medicinal products, replacing a series of similar notifications that had been issued to aid mitigation efforts during the COVID-19 pandemic. During the pandemic, regulatory authorities worldwide—including the Thai Food and Drug Administration (FDA)—reshaped the approval pathway for emergency drugs intended for the treatment of COVID-19. The Thai FDA published five Notifications Re: Conditional Approval for the Emergency Use of Medicinal Products to outline the registration requirements and channels of distribution for drugs intended for the diagnosis, treatment, or prevention of COVID-19. As the threat from COVID-19 was receding, the Thai FDA saw fit to prepare for the potential emergence of other serious communicable diseases by enabling the supply of timely medications for disease diagnosis, treatment, and prevention. The Thai FDA therefore cancelled the five COVID-19-related emergency use notifications, which were published in 2020 and 2022, and replaced them with the Notification Re: Conditional Approval for Emergency Use of Medicinal Products published in May 2023. Under the May 2023 FDA notification on emergency use, conditional approval can be applied to drugs supported by empirical scientific evidence demonstrating their capacity to diagnose, treat, alleviate, cure, or prevent a serious communicable disease. The drugs eligible for approval under this new emergency pathway include novel drugs that are not yet approved in Thailand, as well as existing drugs approved in Thailand but recently discovered to have additional potential indications for the diagnosis, treatment, alleviation, cure, or prevention of a serious communicable disease. Distribution The 2023 FDA notification also clearly defines permissible distribution channels based on the dosage form of drug products: Vaccines can be distributed to governmental organizations that have a duty to prevent or treat diseases, such as the Thai Red Cross Society (TRCS), the Government Pharmaceutical Organization
Read More